UAMS.EDU

Fellow Publications

2016

  1. Al Emam AR, Almomani A, Gilani SA, Khalife WI. Spontaneous Coronary Artery Dissection: One Disease, Variable Presentations, and Different Management Approaches. Int J Angiol. 2016 Sep;25(3):139-47.
  2. Agrawal S, Kasula S, Almomani A, Hacioglu Y, Ahmed Z, Uretsky B, Hakeem A. Clinical and Angiographic Predictors of Persistently Ischemic Fractional Flow Reserve after Percutaneous Revascularization. American Heart Journal. 2016.10.016.
  3. Ayoub K, Nairooz R, Almomani A, Marji M, Paydak H, Maskoun W. Peri-operative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary interruption of Anticoagulation: Evidence from meta-analysis. Journal of Stroke and Cerebrovascular Diseases. 2016 Sep;25(9):2215-21.
  4. Deshmukh A, Pothineni NV, Patel N, Badheka A, Mulpuru SK, Paydak H, Noseworthy PA. Trends in hospitalizations of young patients with atrial fibrillation: A cause for concern? Int J Cardiol. 2016 Jan 15;203:164-5.
  5. Elbadawi A, Gasioch, G, Elgendy IY, Mahmoud AN, Ha LD, Al-Ashry H, Shahin H, Hamza MA, Abuzaid AS, Saad M. Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial. Cardiol Ther. 2016 Dec;5(2):203-213.
  6. Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, Wayanganker SA, Bavry AA. Cardiovascular safety of dipeptidyl-peptidase 4 inhibitors: A meta-analysis of placebo-controlled randomized trials. Am J Cardiovasc Drugs. 2016 Nov 21. [Epub ahead of print].
  7. Garg A, Khunger M, Sinziana S, Chung MK, Tchou P. Incidence of Thromboembolic Complications within 30 days of Direct Current Cardioversion performed less than 48 Hours of Atrial Fibrillation onset. Journal of American College of Cardiology (JACC) Clinical Electrophysiology. 2016;2(4):487-494. doi:10.1016/j.jacep.2016.01.018
  8. Hakeem A, Edupuganti M, Almomani A, Pothineni N, Payne J, Abualsoud A, Bhatti S, Ahmed Z, Uretsky B. Long term prognosis of deferred acute coronary syndrome lesions based on non-ischemic fractional flow reserve. Journal of American Collage of Cardiology (JACC). 2016 Sep 13;68(11):1181-91
  9. Kasula S, Agarwal SK, Hacioglu Y, Pothineni NK, Bhatti S, Ahmed Z, Uretsky B, Hakeem A. Clinical and prognostic value of poststenting fractional flow reserve in acute coronary syndromes. Heart. 2016 Dec 15;102(24):1988-1994.
  10. Mahmoud AN, Saad M, Elgendy IY. Medicare Trends of Takotsubo Cardiomyopathy Outcomes: Is it Just the Tip of an Iceberg?. JACC Heart Fail. 2016;4(7):606.
  11. Mahmoud AN, Elgendy IY, Saad M, Elgendy AY, Barakat AF, Mentias A, Abuzaid A, Bavry AA. Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis. Cardiol Ther. 2016 Nov 28. [Epub ahead of print].
  12. Maskoun W, Pino M, Ayoub K, Llanso O, Almomani A, Nairooz R, Hakeem A, Miller J. Incidence of Atrial Fibrillation after Atrial Flutter Ablation. JACC Electrophysiology. 2016 Nov;2(6):682-90.
  13. Mehta JL, Pothineni NV. Inflammation in heart failure: The holy grail? Hypertension. 2016 May 9.
  14. Nairooz R, Feldman DN, Rochlani Y, Aronow WS, Sardar P, Mukherjee D, Naidu SS, Patel P. Impact of intraprocedural thrombotic events on short- and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. Int J Cardiol. 2016 Jan 1;202:469-76.
  15. Pothineni NV, Shirazi LF, Mehta JL. Gender differences of autonomic control of the cardiovascular system. Curr Pharm Des. 2016 May 18
  16. Pothineni NV, Shah NS, Rochlani Y, Nairooz R, Raina S, Leesar MA, Uretsky BF, Hakeem A. U.S. trends in inpatient utilization of fractional flow reserve and percutaneous coronary intervention. J Am Coll Cardiol. 2016 Feb 16;67(6):732-3.
  17. Pothineni NV, Watts TE, Ding Z, Dai Y, Deshmukh AJ. Eptifibatide-induced thrombocytopenia–when inhibitor turns killer. Am J Ther. 2016 Jan-Feb;23(1):e298-9.
  18. Pothineni NV, Shirazi LF, Mehta JL. Gender Differences in Autonomic Control of the Cardiovascular System. Curr Pharm Des. 2016;22(25):3829-34
  19. Raina S, Lensing SY, Nairooz R, Pothineni NV, Hakeem A, Bhatti S, Pandey T. Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis. JACC Cardiovasc Imaging. 2016 Nov;9(11):1267-1277.
  20. Raina S, Lensing SY, Nairooz RS, Pothineni NV, Hakeem A, Bhatti S, Pandey T. Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis. JACC Cardiovasc Imaging. 2016 Nov;9(11):1267-1277
  21. Rochlani YM, Shah NN, Pothineni NV, Paydak H. Utilization and predictors of electrical cardioversion in patients hospitalized for atrial fibrillation. Cardiol Res Pract. 2016.
  22. Saad M, Nairooz R, Aronow WS. Letter by Saad et al Regarding Article, “Outcomes With Intravascular Ultrasound-Guided Stent Implantation: A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents”. Circ Cardiovasc Interv. 2016 Aug;9(8).
  23. Sardar P, Kundu A, Chatterjee S, Nohria A, Nairooz R, Bangalore S, Mukherjee D, Aronow WS, Lavie CJ. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis. Clinical cardiology 2016 Nov 2.
  24. Sardar P, Chatterjee S, Kundu A, Samady H, Owan T, Giri J, Nairooz R, Selzman CH, Heusch G, Gersh BJ, Abbott JD, Mukherjee D, Fang JC. Remote ischemic preconditioning in patients undergoing cardiovascular surgery: Evidence from a meta-analysis of randomized controlled trials. Int J Cardiol. 2016 Oct 15;221:34-41.
  25. Sen P, Kundu A, Sardar P, Chatterjee S, Nairooz R, Amin H, Aronow WS. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis. Am J Cardiovasc Drugs. 2016 Feb;16(1):33-41.
  26. Shah N, Rochlani Y, Pothineni NV, Paydak H. Burden of arrhythmias in patients with multiple myeloma. Int J Cardiol. 2016 Jan 15;203:305-6.

2015

  1. Abualsuod A, Rutland JJ, Watts TE, Pandat S, Delongchamp R, Mehta JL. The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction. Cardiovascular Drugs and Therapy. 2015 Jun; 29 (3), 265-275.
  2. Agarwal S, Garg A, Parashar A, Tuzcu EM, Kapadia SR. In-hospital Mortality and Stroke Following Surgical Aortic Valve Replacement: A Nationwide Perspective. J Thorac Cardiovasc Surg. 2015 Sep;150(3):571-8.e8.
  3. Ayoub K, Nairooz R. Duration of Triple Therapy: A Clinical Question Remains Unanswered. Clin Cardiol. 2015 Dec;38(12):777.
  4. Ayoub K, Marji M, Nairooz R. Antithrombotic and Antiplatelet Therapy in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention. Am J Cardiol. 2015 Sep 1;116(5):828-9.
  5. Garg A, Parashar A, Agarwal S, Aksoy O, Hammadah M, Poddar KL, Puri R, Svensson LG, Krishnaswamy A, Tuzcu EM, Kapadia SR. Comparison of acute elastic recoil between the SAPIEN-XT and SAPIEN valves in transfemoral-transcatheter aortic valve replacement. Catheterization and cardiovascular interventions. 201515; 85 (3) : 490-6.
  6. Hakeem A, Garg A, Bhatti S, Ahmed Z, Uretsky BF. Fractional flow reserve in acute coronary syndrome: a word of caution. EuroIntervention. 2015 Dec;11(8):e1-2.
  7. Nairooz R, Vallurupalli S, Agrawal M. Letter by Nairooz et al Regarding Article, “Improved Quality of Life After 1 Year With an Invasive Versus a Noninvasive Treatment Strategy in Claudicants: One-Year Results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial”. Circulation. 2015 May 26;131(21):e507.
  8. Nairooz R, Sardar P, Amin H, Chatterjee S, Helmy T, Naidu SS. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2015 Sep;86(3):364-75.
  9. Nairooz R, Sardar P, Aronow WS. Not All NSTEMIs Are Created Equal. J Am Coll Cardiol. 2015 Apr 28;65(16):1718.
  10. Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol. 2015;187:426-9.
  11. Nairooz R, Sardar P, Pino M, Aronow WS, Sewani A, Mukherjee D, Paydak H, Maskoun W. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. Int J Cardiol. 2015;187:345-53.
  12. Nairooz R, Ayoub K, Sardar P, Payne J, Almomani A, Pothineni NV, Shailesh F, Aronow WS, Mukherjee D. Uninterrupted new oral anticoagulants compared to uninterrupted Vitamin K antagonists in ablation of atrial fibrillation, A Meta-analysis. Canadian Journal of Cardiology. 2015; (15):1437-3.
  13. Parashar A, Agarwal S, Krishnaswamy A, Garg A, Poddar KL, Sud K, Ellis S, Tuzcu EM, Kapadia SR. Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction. The American journal of cardiology. 201521; 4 (4): 4.
  14. Pothineni NV, Deshmukh A, Padmanabhan D, Kovelamudi S, Patel NJ, Badheka AO, Mulpuru SK, Paydak H, Noseworthy PA. Complication rates of ventricular tachycardia ablation: Comparison of safety outcomes derived from administrative databases and clinical trials. Int J Cardiol. 2015 Dec 15;201:529-31.
  15.  Pothineni NV, Rochlani Y, Vallurupalli S, Kovelamudi S, Ahmed Z, Hakeem A, Mehta JL. Comparison of angiographic burden of coronary artery disease in patients with versus without hepatitis C infection. Am J Cardiol. 2015 Oct 1;116(7):1041-4.
  16. Pothineni NV, Bahia A, Gobal F, Ahmed Z, Uretsky BF, Hakeem A. “DVT” of the heart: A “novel” treatment for an old problem. JACC Cardiovasc Interv. 2015 Aug 24;8(10):e165-6.
  17. Pothineni NV, Mehta JL. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Sep 3;373(10):977-8.
  18. Pothineni NV, Hayes K, Deshmukh A, Paydak H. Propofol-related infusion syndrome: Rare and fatal. Am J Ther. 2015 Mar-Apr;22(2):e33-5.
  19. Ramineni R, Almomani A, Kumar A, Ahmad M. Role of multimodality imaging in transcatheter aortic valve replacement. Echocardiography. 2015;32(4):677-698.
  20. Rochlani Y, Pothineni NV, Mehta JL. Metabolic syndrome: Does it differ between women and men? Cardiovasc Drugs Ther. 2015 Aug;29(4):329-38.
  21. Sardar P, Chatterjee S, Giri J, Kundu A, Tandar A, Sen P, Nairooz R, Huston J, Ryan JJ, Bashir R, Parikh SA, White CJ, Meyers PM, Mukherjee D, Majersik JJ, Gray WA. Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2015 Sep 14;36(35):2373-80.
  22. Sardar P, Kundu A, Nairooz R, Chatterjee S, Ledley GS, Aronow WS. Health resource variability in the achievement of optimal performance and clinical outcome in ischemic heart disease. Curr Cardiol Rep. 2015 Feb;17(2):1.
  23. Vallurupalli S, Pothineni NV, Deshmukh A, Paydak H. Utility of routine exercise testing to detect rate-related QRS widening in patients without structural heart disease on class ic antiarrhythmic agents (flecainide and propafenone). Am J Cardiol. 2015 Sep 1;116(5):730-2.